Results 121 to 130 of about 20,028 (211)

Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment. [PDF]

J Am Heart Assoc
Yu L, Xiang B, Ren Y, Li Y, Xie J, Zhou X.   +5 more
europepmc   +1 more source

NAT10 promotes gallbladder cancer progression by remodeling cholesterol metabolism via PCSK9 mRNA acetylation. [PDF]

Cell Death Discov
Chen ZY, Wang MY, Ma B, Zhao C, Pan LJ, Wang ZY, Wang YT, Mao PY, Zhao X, Qin DL, Shu YJ, Zhang YJ, Xiang SS, Dong P.   +13 more
europepmc   +1 more source

Lipid-lowering drugs and essential hemorrhagic thrombocythemia's risk: A drug-target Mendelian randomization study. [PDF]

Medicine (Baltimore)
Zhang P, Wang H, Lin M, Dai P, Zhong Q, Wang R, Sheng L, He Z, Nan Z.   +8 more
europepmc   +1 more source

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy. [PDF]

J Am Heart Assoc
Wu T, Zhao X, Xiao M, Deng J, Chen Z, Cheng D, Pan S, Liu X, Wu Y, Huang K.   +9 more
europepmc   +1 more source

Differential expression of GLP1R, PCSK9, and SGLT2 in human aortic versus mitral valve tissues: exploratory findings in calcific aortic valve disease. [PDF]

Front Cardiovasc Med
Cheng SQ, Fu S, Liu NF.
europepmc   +1 more source

LDL receptor-independent mechanisms of proprotein convertase subtilisin/kexin type 9 in cardiovascular pathophysiology. [PDF]

Front Cardiovasc Med
Su H, Guo X, Li Q, Yuan X, Wu X, Zhao Z, Kan Y, Yang Y, Fu Z, Qi Z, Song G.   +10 more
europepmc   +1 more source

Enzyme-Assisted Synthesis and In Vitro Characterization of Bifunctional PCSK9 Inhibitors. [PDF]

Chembiochem
Zhang Y, Wang L, Corcilius L, Reji AK, Payne RJ, Hong B, Durek T, Wang CK, Craik DJ.   +8 more
europepmc   +1 more source

Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies. [PDF]

JACC Adv
Blais JE, Zhong W, Li CYV, Kongkaew C, Chan AHY.   +4 more
europepmc   +1 more source

Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease. [PDF]

J Saudi Heart Assoc
AlHabeeb W, Alamri H, Elbadawi H, AlRuthia YS, Alharbi W, Alshammeri O, Tash A, Almoziny S, Kholaif N, Halawani H, AlMahdi F, Yar W, Alhabib KF.   +12 more
europepmc   +1 more source

Association of achieved LDL-C levels with global coagulability and clinical outcomes in patients with acute coronary syndrome receiving PCSK9 inhibitors: a prospective cohort study. [PDF]

Front Cardiovasc Med
Fu T, Yao S, Zhang S, Linghu H.
europepmc   +1 more source